MedTrace Logo

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

NCT05099822 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-12-14

No results posted yet for this study

Summary

This study aims to evaluate the safety, tolerability, of CC-97489

Conditions

  • Healthy Volunteers

Interventions

DRUG

CC-97489

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-13
Primary Completion
2022-07-11
Completion
2022-07-11

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099822 on ClinicalTrials.gov